Impact Factor
2.88
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
0.70
13,153 total citations
h5-index
114
h5 depth signal
Cited share
16.4%
3,243 of 19,808
Total citations
13,153
Citation footprint
Metric signal
0.68
External metric anchor
Self-citation
0.8%
103 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
48,301
China
8,299
United Kingdom
5,020
Japan
3,766
Germany
3,689
Citing Fields of Research
Oncology
22,014
Cancer & Development
21,052
Breast Cancer
20,407
Immunology
19,617
Cancer, Autophagy & Apoptosis
10,678
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
121,081
Articles tracked across the journal lifetime
Indexed publication set
19,808
3,243 cited publications
Last 12 months
9,114
759.5 publications/month
Open access share
31.9%
2,907 OA publications in the last year
Leading citing country
United States
48,301 citing publications
Leading citing field
Oncology
22,014 citing publications
Latest tracked publication
16 October 2026
10 recent records available
Coverage & Indexing History
v25n6,July 1965-
v25n6,July 1965-
Active Coverage
Active Coverage
Research Focus & Classification
Indexed Subjects
Immunology
Oncology
Cancer & Development
Lung Cancer
Cancer, Autophagy & Apoptosis
Breast Cancer
Issuing & Sponsoring Bodies
Contributor
American Association for Cancer Research
Broad Categories
Neoplasms
Immunology
Cancer, Autophagy & Apoptosis
Cancer & Development
Lung Cancer
Immunotherapy
Genetics & Genomics
Breast Cancer
MeSH Descriptors
Neoplasms
Neoplasms
Neoplasms, Experimental
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1158/0008-5472.can-25-5220
Open DOI
A Machine Learning Framework Enables Supervised Treatment Response Prediction from Tumor Transcriptomics across Cancer Types
Precision oncology aims to guide treatment decisions using biomarkers. Although DNA-based panels are increasingly applied, RNA transcriptomics remains underused because of limited datasets and the absence of robust models. To address thi...
02
DOI 10.1158/0008-5472.can-25-5683
Open DOI
Immunodominant Antiviral T-cell Responses Outcompete Antitumor T-cell Responses to Reduce the Efficacy of Oncolytic Viroimmunotherapy
The paradigm in the field of oncolytic virotherapy proposes that tumor cell killing by an oncolytic virus (OV) culminates in the priming of antitumor CD8+ T cells. However, this ignores the impact a highly immunodominant antiviral respon...
03
DOI 10.1158/0008-5472.can-25-5315
Open DOI
Integrated Organoid CRISPR Screening Reveals NF1 as a Gatekeeper of Cervical Squamous Malignant Transformation
Cervical cancer can progress from high-grade squamous intraepithelial lesions driven by persistent human papillomavirus (HPV) infection. Identifying the gatekeepers restraining malignant transformation could reveal strategies to prevent ...
04
DOI 10.1158/0008-5472.can-26-4373
Open DOI
Antiviral T cells doing double-duty to fight cancer
The exquisite antigen specificity of T cells is one foundation of modern cancer immunotherapy. The therapeutic efficacy of checkpoint blockade, cancer vaccines, and engineered T-cell therapies, all appear to depend on T cells capable of ...
05
DOI 10.1158/0008-5472.can-26-2050
Open DOI
MEKing Room: On the Quest for New Sources of Therapeutic Index in RAS/MAPK-Driven Cancers
The RAS/MAPK pathway is among the most frequently dysregulated in human cancer, predominantly driven by activating mutations across RAS and BRAF in a broad spectrum of tumor types. The recent clinical validation of direct inhibitors of R...
06
DOI 10.1158/0008-5472.can-25-5347
Open DOI
ACKR3 Establishes a Squamous-Restricted Immune Checkpoint Axis in Lung Squamous Cell Carcinoma
Lung squamous cell carcinoma (LUSC) is an aggressive subtype of non–small cell lung cancer with limited targeted therapeutic options and incompletely defined immune-regulatory dependencies. Here, we identified atypical chemokine receptor...
07
DOI 10.1158/0008-5472.can-26-0860
Open DOI
ARID2 Loss Reprograms the Kynurenine-AhR Pathway to Restore Antitumor Immunity in CTNNB1-Mutant Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) driven by gain-of-function mutations in CTNNB1 (CTNNB1GOF) that stabilize β-catenin exhibits a profoundly immunosuppressive tumor microenvironment (TME), rendering it resistant to immune checkpoint blockade...
08
DOI 10.1158/0008-5472.can-26-0507
Open DOI
KAT5 is Dual-Function Therapeutic Target with Direct Antitumor and Immunomodulatory Activity in Endometrial Cancer
Epigenetic dysregulation plays a vital role in the progression of endometrial cancer (EC), yet targeted treatment options remain limited. Here, we identified the histone acetyltransferase KAT5 as a therapeutic target in EC. KAT5 was sign...
09
DOI 10.1158/0008-5472.can-25-5866
Open DOI
A Germline-Encoded lncRNA-Mitochondrial Axis Rewires Oxidative Phosphorylation to Drive Progression in Clear Cell Renal Cell Carcinoma
Clear cell renal cell carcinoma (ccRCC) is characterized by profound metabolic reprogramming and substantial inherited susceptibility. The molecular mechanisms linking germline risk variation to tumor metabolic reprogramming could potent...
10
DOI 10.1158/0008-5472.can-25-5766
Open DOI
A syngeneic murine glioma model recapitulates key molecular, immunologic, and functional features of human glioblastoma to enable therapeutic development
Glioblastoma (GBM) is the most common and deadly primary brain tumor in adults, characterized by diffuse infiltrative lesions, distinct oncogenic alterations, and a suppressive tumor immune microenvironment (TIME). These traits, however,...
Bibliographical & Catalog Notes
Imprint varies.
Print issues ceased with v. 80, no. 24 (Dec. 2020).
Some issues accompanied by monographic supplements and numbered as pt. 2 of that issue.
Available also online.
Official organ of the American Association for Cancer Research.
Indexes: Vols. 1-10, 1941-50. 1 v; Vols. 11-25, 1951-65. 1 v; Vols. 26-30, 1966-70. 1 v.
Vol. 55, no. 7 (APR1 1995)19950519 Notice not published Printed on acid-free paper